Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mereo Biopharma Group Plc (MREO – Research Report) and PAVmed (PAVM – Research Report).
Mereo Biopharma Group Plc (MREO)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Mereo Biopharma Group Plc yesterday and set a price target of $7.00. The company’s shares closed last Wednesday at $3.17.
According to TipRanks.com, Kluska is a 5-star analyst with an average return of
Mereo Biopharma Group Plc has an analyst consensus of Strong Buy, with a price target consensus of $6.25, implying a 109.0% upside from current levels. In a report issued on April 30, BTIG also maintained a Buy rating on the stock with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
PAVmed (PAVM)
In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Hold rating on PAVmed, with a price target of $4.00. The company’s shares closed last Wednesday at $1.90, close to its 52-week low of $1.60.
According to TipRanks.com, Osborn ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
PAVmed has an analyst consensus of Strong Buy, with a price target consensus of $10.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MREO:
- Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
- Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
